A Phase 3 interventional study of TNX-102 SL and Placebo SL Tablet in Fibromyalgia, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 39 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-08.
Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.
Among the 369 studies in Fibromyalgia with a site in United States, this one is the 25th largest by enrollment of the 320 interventional ones that give a count, is one of 16 that started in 2019, is one of 55 in phase 3, and was the 268th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Spaulding Rehabilitation Hospital · Sites in United States
Ages 21–65
Pulkit Grover · Sites in United States
Ages 18–65
Theranica · Sites in United States, Israel
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 61 · Phase 3 64 · Phase 4 24
First in 1994; this study’s year is marked. 16 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 503 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 72 across the 320 interventional studies, 200 across the 47 observational. Of the 276 that completed or were terminated, 116 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 369 have an industry lead sponsor. The 10 most frequent:
Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Tonix Pharmaceuticals, Inc. has 8 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
29 of the studies in Fibromyalgia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT07116278University of California, San FranciscoTMS-EEG Biomarkers for Chronic Pain | 2026-12 |
| NCT04949100Paul CrawfordMicrocurrent for Fibromyalgia | 2026-12 |
| NCT07525063Duke UniversityPain & Reward Neuromodulation of CNS Circuits | 2026-12 |
| NCT06552728University of California, IrvineThe Effects of Energy Healing in Fibromyalgia | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 369 studies in Fibromyalgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
Drug: TNX-102 SL
1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
Drug: Placebo SL Tablet
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Also known as: Low dose cyclobenzaprine sublingual tablets
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Also known as: Placebo sublingual tablets
Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.
Patients provide a daily numeric assessment of their average pain (24-hour recall), via an electronic diary, using an 11-point NRS. Scores range from 0 (no pain) to 10 (worst possible pain).
Time frame: 14 weeks
Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved"
The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.
Time frame: 14 weeks
Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score
The FIQ-R is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.
Time frame: 14 weeks
Change From Baseline to Week 14 in the FIQR Function Domain Score
The FIQ-R is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.
Time frame: 14 weeks
Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance
The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.
Time frame: 14 weeks
Change From Baseline to Week 14 in the PROMIS Score for Fatigue
The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.
Time frame: 14 weeks
Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality
Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).
Time frame: 14 weeks
| Milestone | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Started | 248 | 255 |
| Completed | 204 | 213 |
| Not completed | 44 | 42 |
| Withdrew: Adverse event | 21 | 9 |
| Withdrew: Lack of efficacy | 2 | 8 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 12 | 11 |
| Withdrew: Lost to follow-up | 4 | 9 |
| Withdrew: Covid-19 related crisis | 3 | 3 |
| Withdrew: Subject non-compliance | 1 | 1 |
| Withdrew: Family emergency | 1 | 0 |
Patients provide a daily numeric assessment of their average pain (24-hour recall), via an electronic diary, using an 11-point NRS. Scores range from 0 (no pain) to 10 (worst possible pain).
| score on a scale | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. | -1.9 (-2.1 to -1.7) | -1.5 (-1.7 to -1.3) |
The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.
| Participants | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved" | 93 | 75 |
The FIQ-R is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.
| score on a scale | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score | -18.4 (-20.8 to -16.0) | -14.0 (-16.4 to -11.7) |
The FIQ-R is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.
| score on a scale | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Change From Baseline to Week 14 in the FIQR Function Domain Score | -13.6 (-16.1 to -11.2) | -9.3 (-11.7 to -6.8) |
The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.
| score on a scale | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance | -9.5 (-10.7 to -8.2) | -6.5 (-7.7 to -5.4) |
The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.
| score on a scale | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Change From Baseline to Week 14 in the PROMIS Score for Fatigue | -8.0 (-9.1 to -6.9) | -6.2 (-7.4 to -5.0) |
Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).
| score on a scale | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality | -2.0 (-2.3 to -1.8) | -1.5 (-1.7 to -1.2) |
Collected over 14 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TNX-102 SL Tablets, 5.6 mg | 0/248 (0%) | 2/248 (0.8%) | 70/248 (28.2%) |
| Placebo SL Tablet | 0/255 (0%) | 5/255 (2%) | 3/255 (1.2%) |
| Event | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Spinal compression fractureInjury, poisoning and procedural complications | 1/248 | 0/255 |
| PneumoniaInfections and infestations | 1/248 | 0/255 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 1/248 | 0/255 |
| Coeliac artery compression syndromeGastrointestinal disorders | 0/248 | 1/255 |
| Corona virus infectionInfections and infestations | 0/248 | 1/255 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/248 | 1/255 |
| HypotentionVascular disorders | 0/248 | 1/255 |
| ColitisGastrointestinal disorders | 0/248 | 1/255 |
| Femur fractureInjury, poisoning and procedural complications | 0/248 | 1/255 |
| Foot fractureInjury, poisoning and procedural complications | 0/248 | 1/255 |
| Event | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Hypoaesthesia oralGastrointestinal disorders | 43/248 | 1/255 |
| Paraesthesia oralGastrointestinal disorders | 14/248 | 1/255 |
| DysguesiaNervous system disorders | 13/248 | 1/255 |
| Age, Continuous(years) | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet | Total |
|---|---|---|---|
| Mean | 50.0 ± 9.40 | 49.3 ± 10.16 | 49.6 ± 9.79 |
| Sex: Female, Male(Participants) | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet | Total |
|---|---|---|---|
| Female | 232 | 247 | 479 |
| Male | 16 | 8 | 24 |
| Race (NIH/OMB)(Participants) | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 2 | 5 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 19 | 20 | 39 |
| White | 222 | 216 | 438 |
| More than one race | 3 | 9 | 12 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Region of Enrollment(participants) | TNX-102 SL Tablets, 5.6 mg | Placebo SL Tablet | Total |
|---|---|---|---|
| United States | 248 | 255 | 503 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2019 to primary completion in Oct 2020, 10 months.
Results were first posted in Aug 2022, 1 year 9 months after primary completion.
Of 17 phase 3 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine